Lazard nets Merill Lynch V-P Creswell for comms
30 Apr 2004 | by Tom Williams
US investment bank Lazard has poached Merrill Lynch vice-president of media relations Richard Creswell to head its communications in London.
Click
to remove filters
LONDON - WPP Group has reported revenues for the first quarter of the year up by nearly 6%, including a 12% rise in the UK, and said there are signs that an increasing number of new-business opportunities.
US investment bank Lazard has poached Merrill Lynch vice-president of media relations Richard Creswell to head its communications in London.
Chinese fund management and corporate turnaround specialist China Asset Management (CAM) has hired the Public Image Group to handle a global investor relations programme.
Financial Dynamics has appointed Hawkpoint Partners finance director Sanjay Jawa as the firm moves to plug the gap in its management left by the departures of chief operating officer Steve Jacobs and chief financial officer Dana Mulvihill.
I doubt whether six months ago many people in the UK had heard of Russian businessman Alisher Usmanov, let alone had a clue how he made his fortune. Then he decided to buy a stake in Corus, the UK end of a company still better known as British Steel, and tried to get a director on the board.
Schering-Plough is set to launch a PR offensive to promote its blockbuster over-the-counter anti-histamine brand Clarityn Allergy.
PR budget-holders at client companies must be better educated about media relations best practice, according to a former Sunday Mirror assistant editor.
Healthcare specialist hsd communications has launched the first UK consumer and trade PR campaign for the New Chapter food supplements range.
The NHS document published last year is back in the news. Why? Health minister Rosie Winterton referred to it last week when she urged men to visit their local chemist. She wants pharmacies to be seen as valuable providers of advice.
US drugs giant Eli Lilly has appointed Packer Forbes Communications to handle UK pre-launch PR for potential blockbuster anti-depressant Cymbalta, the much anticipated successor to its now off-patent Prozac.